CAG
CRL icon

Csenge Advisory Group’s Charles River Laboratories CRL Stock Holding History

Csenge Advisory Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,478
Closed -$316K – 613
2022
Q2 		$316K Sell
1,478
-715
-33% -$175K 0.03% 437
2022
Q1 		$623K Buy
2,193
+530
+32% +$163K 0.05% 325
2021
Q4 		$620K Sell
1,663
-49
-3% -$19K 0.06% 292
2021
Q3 		$713K Buy
1,712
+49
+3% +$20.4K 0.06% 292
2021
Q2 		$620K Buy
1,663
+310
+23% +$104K 0.06% 293
2021
Q1 		$415K Sell
1,353
-25
-2% -$6.95K 0.04% 323
2020
Q4 		$344K Sell
1,378
-196
-12% -$46.7K 0.04% 294
2020
Q3 		$367K Buy
1,574
+5
+0.3% +$1.04K 0.05% 261
2020
Q2 		$274K Sell
1,569
-528
-25% -$84.3K 0.04% 290
2020
Q1 		$265K Buy
2,097
+743
+55% +$111K 0.07% 234
2019
Q4 		$207K Buy
+1,354
New +$187K 0.05% 274
2018
Q4 		– Sell
-714
Closed -$91K – 461
2018
Q3 		$91K Buy
+714
New +$88.1K 0.04% 246

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Csenge Advisory Group's CRL Position: Q3 2022 in Review

Csenge Advisory Group sold out of Charles River Laboratories (CRL) in Q3 2022, closing a stake of 1,478 shares — an estimated $316K sold.

Csenge Advisory Group first reported a position in CRL in Q3 2018 and held it in 12 quarters. The position peaked at $713K in Q3 2021. 582 funds tracked by Wall St. Rank hold CRL as of Q3 2022.

  • Csenge Advisory Group reported no remaining Charles River Laboratories position as of Q3 2022 after selling out during the quarter.
  • Csenge Advisory Group sold 1,478 Charles River Laboratories shares in Q3 2022, an estimated $316K.
  • Csenge Advisory Group first reported a position in Charles River Laboratories in Q3 2018 and held it in 12 quarters.
  • Csenge Advisory Group's Charles River Laboratories position peaked at $713K in Q3 2021.
  • 582 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2022.

Based on Csenge Advisory Group's 13F filing for Q3 2022, filed 4 Oct 2022.